The major challenge to using ALK IHC is the often low-level expression of ALK fusion proteins in ALK-rearranged NSCLC [16], which makes it necessary to develop more sensitive IHC-based methods. The gene discussed is ALK; the disease is non-small cell lung carcinoma.